Exact Sciences Corp. (NASDAQ:EXAS) had its price objective lifted by analysts at Jefferies Group from $20.00 to $23.00 in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective indicates a potential upside of 22.02% from the stock’s previous close.

Several other analysts also recently weighed in on EXAS. BTIG Research reaffirmed a “buy” rating and issued a $9.00 target price on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Mizuho reaffirmed a “hold” rating and issued a $6.50 target price on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Canaccord Genuity reaffirmed a “buy” rating and issued a $12.00 target price (up previously from $9.00) on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Roth Capital reaffirmed a “hold” rating and issued a $7.00 target price on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Finally, William Blair reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $16.54.

Analyst Recommendations for Exact Sciences Corp. (NASDAQ:EXAS)

Shares of Exact Sciences Corp. (NASDAQ:EXAS) traded up 2.76% during mid-day trading on Tuesday, reaching $19.37. 840,871 shares of the company traded hands. The stock’s 50-day moving average is $19.57 and its 200-day moving average is $12.21. Exact Sciences Corp. has a 52 week low of $4.67 and a 52 week high of $22.80. The company’s market capitalization is $1.90 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.09. Exact Sciences Corp. had a negative net margin of 277.74% and a negative return on equity of 57.16%. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $18.54 million. During the same period last year, the firm posted ($0.44) EPS. Exact Sciences Corp.’s revenue for the quarter was up 161.7% on a year-over-year basis. On average, equities analysts predict that Exact Sciences Corp. will post ($1.79) EPS for the current fiscal year.

In other news, COO Maneesh Arora sold 7,359 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.82, for a total value of $109,060.38. Following the completion of the transaction, the chief operating officer now owns 538,736 shares of the company’s stock, valued at $7,984,067.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Graham Peter Lidgard sold 7,383 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.82, for a total transaction of $109,416.06. Following the completion of the transaction, the insider now directly owns 227,592 shares of the company’s stock, valued at approximately $3,372,913.44. The disclosure for this sale can be found here. 5.60% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of the stock. ProShare Advisors LLC raised its position in Exact Sciences Corp. by 0.9% in the second quarter. ProShare Advisors LLC now owns 11,843 shares of the company’s stock worth $145,000 after buying an additional 103 shares in the last quarter. Amalgamated Bank raised its position in Exact Sciences Corp. by 1.5% in the second quarter. Amalgamated Bank now owns 10,229 shares of the company’s stock worth $213,000 after buying an additional 148 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in Exact Sciences Corp. by 0.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 77,280 shares of the company’s stock worth $947,000 after buying an additional 457 shares in the last quarter. BlackRock Japan Co. Ltd raised its position in Exact Sciences Corp. by 1.2% in the first quarter. BlackRock Japan Co. Ltd now owns 101,740 shares of the company’s stock worth $686,000 after buying an additional 1,216 shares in the last quarter. Finally, Nationwide Fund Advisors raised its position in Exact Sciences Corp. by 2.5% in the second quarter. Nationwide Fund Advisors now owns 63,002 shares of the company’s stock worth $772,000 after buying an additional 1,555 shares in the last quarter. 86.91% of the stock is owned by institutional investors and hedge funds.

About Exact Sciences Corp.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

5 Day Chart for NASDAQ:EXAS

Receive News & Stock Ratings for Exact Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corp. and related stocks with our FREE daily email newsletter.